Mitsubishi UFJ Asset Management UK Ltd. Invests $1.33 Million in Masimo Corporation (NASDAQ:MASI)

Key Points

• Mitsubishi UFJ Asset Management UK Ltd. has invested approximately $1.33 million in Masimo Corporation by acquiring 8,000 shares in the 1st quarter.
• Masimo reported an earnings per share (EPS) of $1.33 for the recent quarter, which exceeded analysts' expectations of $1.22, and reflected a 7.7% increase in revenue year-over-year.
• Despite several positive ratings, including a "buy" rating from some brokerages, the stock has seen varied price target adjustments, with an average target price of $193.60.

Mitsubishi UFJ Asset Management UK Ltd. bought a new position in Masimo Corporation (NASDAQ:MASI - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,000 shares of the medical equipment provider's stock, valued at approximately $1,333,000.

Several other institutional investors and hedge funds also recently modified their holdings of MASI. Farther Finance Advisors LLC lifted its stake in shares of Masimo by 128.9% in the first quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 116 shares in the last quarter. NBC Securities Inc. acquired a new position in shares of Masimo in the first quarter worth about $61,000. UMB Bank n.a. lifted its stake in shares of Masimo by 134.0% in the first quarter. UMB Bank n.a. now owns 447 shares of the medical equipment provider's stock worth $74,000 after acquiring an additional 256 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Masimo by 58.4% in the first quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider's stock worth $123,000 after acquiring an additional 272 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Masimo in the fourth quarter worth about $163,000. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Stock Performance

Shares of MASI stock opened at $155.96 on Thursday. Masimo Corporation has a 12-month low of $107.98 and a 12-month high of $194.88. The firm has a market capitalization of $8.47 billion, a price-to-earnings ratio of -18.31 and a beta of 1.21. The business has a 50 day simple moving average of $161.70 and a 200 day simple moving average of $164.24. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.11. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%. The business had revenue of $370.90 million during the quarter, compared to analyst estimates of $368.65 million. During the same period in the prior year, the company posted $0.86 EPS. The business's revenue for the quarter was up 7.7% compared to the same quarter last year. On average, equities research analysts anticipate that Masimo Corporation will post 4.1 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on MASI. Wall Street Zen cut Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Raymond James Financial dropped their price target on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. BTIG Research reiterated a "buy" rating on shares of Masimo in a research report on Monday, July 14th. Piper Sandler increased their price target on Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Finally, Wells Fargo & Company dropped their price target on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $193.60.

Insider Transactions at Masimo

In other Masimo news, Director William R. Jellison acquired 3,000 shares of the firm's stock in a transaction that occurred on Monday, August 11th. The stock was acquired at an average cost of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director directly owned 4,790 shares of the company's stock, valued at $699,244.20. This represents a 167.60% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.70% of the stock is owned by company insiders.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.